{
  "ticker": "AZN",
  "company_name": "AstraZeneca PLC",
  "event_date": "2026-01-13",
  "event_window_days": 30,
  "trial": {
    "nct_id": "NCT06103877",
    "phase": "PHASE1",
    "enrollment_count": 108,
    "enrollment_type": "ACTUAL",
    "study_type": "INTERVENTIONAL",
    "conditions": [
      "Healthy Volunteers"
    ],
    "has_results": false,
    "brief_title": "A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers",
    "official_title": "A Phase I, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of AZD1163 Administered as Single and Multiple Ascending Doses in Healthy Volunteers",
    "sponsor": "AstraZeneca",
    "primary_completion_date": "2026-01-13",
    "completion_date": "2026-01-13"
  }
}